

JACQUES B. ROTTEMBOURG, VINCENT LAUNAY-VACHER,
and JULIEN MASSARD
Paris, France

Correspondence to Jacques B. Rottembourg, Department of Nephrology, Hôpital de la Pitié, 75013 Paris, France.
E-mail: Jacques.rottembourg2@libertysurf.fr

REFERENCES

1. TAKAHASHI Y, TANAKA A, NAKAMURA T, *et al*: Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. *Kidney Int* 65:1099–1104, 2004
2. CHERTOW GM, BURKE SK, LAZARUS JM, *et al*: Polyallylamine hydrochloride (Renagel): A non calcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. *Am J Kidney Dis* 29:66–71, 1997
3. KNIP M, DOUEK IF, MOORE WPT, *et al*: Safety of high-dose nicotinamide: A review. *Diabetologia* 43:1337–1345, 2000
4. WAKASUGI H, FUTAMI T, MUSO E, *et al*: Thrombocytopenia and anemia induced by niceritrol used for amelioration of hyperphosphatemia in a hemodialysis patient. *Nephron* 86:97–98, 2000
5. O'BRIEN T, SILVERBERG JD, NGUYEN TT: Nicotinic acid-induced toxicity associated with cytopenia and decreased level of thyroxine-binding globulin. *Mayo Clin Proc* 67:465–468, 1992

Muscle IGF-I levels in hemodialysis patients

To the Editor: We read with great interest Wang *et al*'s paper [1] describing reduced skeletal muscle mRNA levels for insulin-like growth factor (IGF)-IEa, IGF-II, and the IGF type 1 receptor in hemodialysis (HD) patients. While the low levels of IGF-IEa mRNA relative to healthy controls is anticipated, the elevated muscle IGF-I protein level (mIGF-I) reported is at odds with the diminished levels, relative to healthy controls previously reported in our HD patients [2] and animal models of chronic renal failure (CRF) (e.g. [3]). An obvious difference between these studies is that in contrast to our patients and CRF rats, the HD patients recruited by Wang *et al* were not muscle wasted. This supports our contention that mIGF-I may play an important role in muscle atrophy in CRF populations.

Notwithstanding species and methodologic differences, we were also surprised by the huge disparity in mean mIGF-I levels reported by this group for HD patients and CRF rats [1, 3]. Assuming a protein content of 15.5% in wet skeletal muscle for nonobese humans [4], the 131 and 100 ng IGF-I/mg wet muscle values reported by Wang *et al* convert to 845 and 645 ng IGF-I/mg muscle protein for HD patients and controls, respectively. These values are 1 to 2×10^5 greater than those reported by Ding *et al* (0.0042 and 0.0069 ng/mg muscle protein for CRF

and control rats, respectively). Are the units correctly stated in these papers? Additionally, the serum IGF values in Wang *et al*'s paper need to be reported as ng/mL, not $\mu\text{g/mL}$, to be correct.

ANDREW B. LEMMEY, JAMIE H. MACDONALD, SAMUELE M. MARCORÀ, and MAHDI JIBANI
Gwynedd, United Kingdom

Correspondence to Andrew B. Lemmey, School of Sport, Health and Exercise Sciences, University of Wales-Bangor, George Building, Holyhead Rd., Bangor, Gwynedd, UK LL57 2PZ.
E-mail: a.b.lemmey@bangor.ac.uk

REFERENCES

1. WANG HH, CASABURI R, TAYLOR WE, *et al*: Skeletal muscle mRNA for IGF-IEa, IGF-II, and IGF-I receptor in decreased in sedentary chronic hemodialysis patients. *Kidney Int* 68:352–361, 2005
2. MACDONALD JH, PHANISH MK, MARCORÀ SM, *et al*: Muscle insulin-like growth factor status, body composition, and functional capacity in haemodialysis patients. *J Renal Nutr* 14:248–252, 2004
3. DING H, GAO X-L, HIRSCHBERGER R, *et al*: Impaired action of insulin-like growth factor I on protein synthesis and degradation in skeletal muscle of rats with chronic renal failure. Evidence for a postreceptor defect. *J Clin Invest* 97:1064–1075, 1996
4. MINGRONE G, BERTUZZI A, CAPRISTO E, *et al*: Unreliable use of standard muscle hydration value in obesity. *Am J Physiol-Endo* 280:365–371, 2001

Anti-proteinase 3 antibody binding to neutrophils as demonstrated by confocal microscopy

To the Editor: We read with great interest the article by Van Rossum *et al* [1] and wish to provide supplementary microscopic evidence of binding of anti-neutrophil cytoplasm antibodies (ANCA) to a subset of neutrophils.

Following the report by Abdel-Salam *et al* [2] of a failure of ANCA to bind to neutrophils, we investigated binding of anti-PR3 antibody positive serum from patients with systemic vasculitis to human neutrophils using indirect immunofluorescence and confocal microscopy, as detailed in Figure 1. The priming and staining procedure was virtually identical to that used by Van Rossum *et al*, with the addition of an incubation step with the neutrophil marker CD16. Our results support their findings, with membrane staining of a fraction of neutrophils incubated with anti-PR3-positive serum. Thus, the hypothesis that ANCA binding *in vivo* results in dysregulated degranulation of neutrophils [3] remains viable.